MIT Technology Review Subscribe

Seeing Signs of Diabetes

Molecular traces spot the disease.

Scientists estimate that patients with type 1 or type 2 diabetes have already lost 50 to 90 percent of their insulin-­producing cells by the time their conditions are diagnosed. A new molecular tracer could provide the first clear view of these cells in the pancreas, helping doctors detect and treat diabetes far earlier.

Preliminary tests show that PET scans using a new molecular tracer can distinguish between rats with healthy levels of insulin-­producing cells in the pancreas (glowing areas above) and rats whose ­insulin-producing cells have been chemically damaged.

The tracer was developed by Hank Kung, a scientist at the University of Pennsylvania. It binds to a receptor inside the cells and is tagged with a radioactive label that can be detected using positron emission tomography (PET).

Advertisement

Preliminary tests show that PET scans using the tracer can distinguish between rats with healthy levels of insulin-­producing cells in the pancreas (glowing areas in the image at left) and rats whose ­insulin-producing cells have been chemically damaged.

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in

“If we could see cell loss early, perhaps we could get patients started on therapy before there is irreversible damage,” says Dan ­Skovronsky, founder and CEO of Avid Radiopharmaceuticals, the Philadelphia company that is developing the tracer.

This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement